Acute Gout Flare Management in Dialysis Patients

Primary Treatment: Oral Corticosteroids

The European League Against Rheumatism (EULAR) recommends prednisone or prednisolone at 0.5 mg/kg/day (typically 30-35 mg daily) for 5-10 days as the safest and most effective oral option for dialysis patients with acute gout flares 1, 2
This dosing has demonstrated equivalence to NSAIDs in randomized trials for treating acute gout flares 1
No dose adjustment is required for renal impairment 2
The treatment can be given as full dose for 2-5 days then tapered over 7-10 days, or as full dose for 5-10 days then stopped 2

Colchicine must be avoided entirely if the patient is taking strong P-glycoprotein or CYP3A4 inhibitors (cyclosporin, clarithromycin, ketoconazole, ritonavir, verapamil) 1, 3
Co-prescription with these agents dramatically increases colchicine plasma concentrations and risk of serious toxicity 1
Patients on statins require heightened monitoring for neurotoxicity and muscular toxicity 4, 5

Urate-lowering therapy (ULT) is indicated given the presence of tophi 4, 5
Febuxostat is preferred over allopurinol in severe renal impairment, as allopurinol dosing limitations may reduce efficacy 4, 5
Target serum uric acid <5 mg/dL (300 μmol/L) to facilitate faster crystal dissolution in severe tophaceous gout 4, 5
Prophylaxis against flares should be initiated with ULT and continued for at least 6 months after achieving target urate with no tophi detected 2, 4, 6